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of clinical skin examination within the prior 
three years and reduced incidence of thick mel-
anomas (Aitken et al., 2010). This year, Katalinic 
and colleagues (in press) reported the substan-
tial reduction in melanoma mortality associ-
ated with the statewide skin cancer screening by 
clinical full-body skin examination in Schleswig-
Holstein, Germany. Similar reductions in mortal-
ity were not observed in the regions immediately 
to the north, south, east, and west that did not 
have melanoma screening programs. This is the 
strongest evidence yet that population-based 
melanoma screening can reduce mortality.
Early detection may be limited by the focus 
on “ABCD” for early detection instead of the 
broader “new or changing skin lesions” (change 
in size, shape, or color) and the “ugly duckling” 
sign. With the combination of monthly thorough 
skin self-examination; periodic clinical full-
body skin examination, at least for those at high 
risk; and appropriate use of adjunctive technol-
ogy, early detection efforts may be substantially 
improved. Nevertheless, there are some melano-
mas for which effective early detection by visual 
inspection may not be possible, such as certain 
subsets of nodular, desmoplastic, and amelanot-
ic melanomas, as well as those with no known 
cutaneous primary (Curiel-Lewandrowski et al., 
2012). The proportion of melanomas that cannot 
be detected at a curable phase may be small but 
is unknown.
Standards of evidence and the US Preventive 
Services task Force
None of the studies of melanoma screening pro-
grams mentioned above was a randomized trial; 
hence, they do not represent the most rigorous 
category of medical evidence. In particular, the 
US Preventive Services Task Force (USPSTF) 
declared as recently as 2009 that evidence was 
insufficient to recommend for or against skin 
cancer screening (USPSTF, 2009). Because of 
the high standards of evidence to which the 
USPSTF adheres, they frequently reach conclu-
sions of “insufficient evidence.” To address the 
reducing death from melanoma
The primary reason we are concerned about 
melanoma, and the justification behind new and 
expensive therapies, is that melanoma kills peo-
ple; furthermore, the people it kills are often in 
the prime of life, younger than the typical patient 
who dies from cancer. The number of melanoma 
deaths in the United States is estimated to be 
more than 9,000 in 2012, higher than in 2000, 
and the age-adjusted death rate has not changed 
substantially over these dozen years. Altogether, 
100,000 Americans have succumbed to mela-
noma since 2000. We must cut the mortality rate 
by at least half, but progress toward that goal has 
been elusive.
The key to achieving this goal is early detec-
tion, because prevention, if it is ever to be 
effective, takes a very long time, and curative 
therapy, despite recent progress, remains an 
unrealized hope for most patients who have 
recurrent disease. Early detection itself is chal-
lenging, however, which may explain the lack of 
progress in reducing mortality rates (Criscione 
and Weinstock, 2010). Effective early detection 
requires someone (typically a clinician, patient, 
or family member) to inspect the skin and to 
recognize skin lesions that may represent early 
disease, when melanoma is highly curable with 
simple surgical excision (Weinstock, 2000).
The evidence to support early detection of 
melanoma by full-body skin inspection has 
recently strengthened considerably. In 2008, 
Schneider and colleagues published the expe-
rience of the Lawrence Livermore National 
Laboratories workforce, which demonstrated a 
decreased incidence rate of thicker melanomas 
and decreased melanoma mortality in asso-
ciation with institution of a screening program 
(Schneider et al., 2008). In 2010, Aitken and col-
leagues published a case–control study that doc-
umented an association between performance 
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resulting insufficiency of guidance provided, they have iden-
tified certain domains relevant to the issues they declared 
to have insufficient evidence for a recommendation. These 
include potential preventable burden and potential harm 
associated with the intervention being evaluated (Petitti et 
al., 2009).
However, the USPSTF has failed to adjust explicitly the 
standard of evidence they require for a recommendation 
based on the domains they identified, such as preventable 
burden and potential harms, and they should do so. In par-
ticular, the potential harms of skin examination are modest. 
There are certainly potential harms from a false-positive skin 
cancer screen, but these are not comparable to the potential 
harms of, for example, spiral computed tomography or colo-
noscopy. The latter is associated with considerable morbid-
ity as compared with a skin examination and, indeed, would 
constitute a major violation were all parties not convinced 
of its net health (and potentially lifesaving) benefit to the 
patient.
Efforts to improve skin self-examination have been asso-
ciated with increased surgery on the skin (Weinstock et al., 
2007) and hence with increased morbidity and cost. The 
statewide skin cancer screening campaign focused on phy-
sician-performed full-body skin examination reported by 
Waldman et al. (2012) was associated with increased inci-
dence of melanoma and therefore with potential morbidity 
and costs. In this respect, melanoma screening resembles 
other cancer screening activities, such as lung cancer screen-
ing (National Lung Screening Trial Research Team, 2011). The 
potential harms of melanoma screening call for some level of 
evidence that benefits exceed harms to support advocacy of 
skin cancer screening, but not the same level of evidence as 
for procedures with greater potential harm.
Perhaps the USPSTF realizes this. Its 2009 declaration that 
“the evidence is insufficient to recommend for or against 
routine screening for skin cancer using a total body skin 
examination” was followed by the statement that “clinicians 
should remain alert for skin lesions with malignant features” 
(USPSTF, 2009), despite the absence of trials assessing the 
melanoma-detection abilities of “alert” clinicians.
The USPSTF fails in a second respect in the context of mel-
anoma screening, by inadequately accounting for the ambi-
guity of skin examination. When primary care physicians 
examine patients, they inevitably look at some areas of skin, 
and if the patient has an obvious melanoma on the areas 
examined, it would presumably be recognized and managed 
appropriately. Skin examination frequently occurs in this 
casual and generally nonmethodical manner apart from any 
intent to maximize melanoma detection. Skin self-examina-
tion is similar in this respect (Weinstock, 2000). These com-
mon, informal activities become formal screening if done in 
a more rigorous manner (i.e., more thoroughly and purpose-
fully). Hence, the issue is not whether skin inspection—either 
clinical skin examination or skin self-examination—should 
be done, but whether to recommend it be done regularly and 
systematically with an awareness of warning signs for mela-
noma, as opposed to performing it in a casual and potentially 
error-prone manner.
The 2009 publication by the USPSTF was based on a 
review of published literature through 2005. Therefore, the 
USPSTF did not consider the more recent publications ref-
erenced above. Although scientists working with at-risk 
populations around the globe seek better documentation of 
potential benefits, harms, and costs, it is unlikely that a large, 
traditional randomized trial with melanoma mortality as an 
end point will be funded. We should reevaluate the role of 
other types of evidence in making recommendations for con-
ducting casual versus thorough inspections of skin, where 
the potential harms of thorough inspection are modest. This 
reevaluation should lead to a recommendation for or against 
melanoma screening or a recommendation for a realistic 
path to obtaining the additional evidence sufficient to justify 
such a recommendation. The thousands of melanoma deaths 
every year impel us to do so.
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